Talazoparib will become the NHS’s first targeted treatment for advanced breast cancers caused by mutations to BRCA genes, after a recommendation by the National Institute for Health and Care Excellence.
[Cancer Research UK]
Home Newsletters Cancer Stem Cell News NHS Offers First Drug Targeting Advanced Breast Cancers Driven by BRCA Gene...
